QuantHealth raises $45 million Series B to bring AI simulations to the costly world of clinical trials
The Israeli startup says its technology has simulated more than 600 trials and can help drugmakers test decisions before enrolling patients or spending billions on development.
QuantHealth, which develops AI-based simulations for clinical trials, has raised $45 million in a Series B funding round led by growth fund Qumra Capital, with participation from additional investors including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures and Esplanade Ventures.
The latest round brings the Israeli company’s total funding raised to $75 million. Previous investors include pharmaceutical giant Sanofi and Accenture Ventures, the investment arm of consulting firm Accenture.
QuantHealth plans to use the new capital to expand its research and development capabilities, develop next-generation AI models, increase its datasets and broaden its therapeutic coverage. The company also intends to expand its workforce and extend its product offering across the drug development lifecycle, from clinical trial design to commercial planning.
The company was founded in 2020 by Orr Inbar, who previously worked at ConcertAI, and Arnon Horev, who previously led business operations at life sciences company Nucleai and managed marketing and sales at medical technology company EarlySense. The company currently employs approximately 85 people in offices in New York and Tel Aviv.
Clinical trials remain one of the most expensive and uncertain stages of drug development. More than 90% of drugs that enter clinical development ultimately fail, with approximately 75% of failures attributed to efficacy and safety issues. Faced with rising development costs, increasing competition and pressure to bring new therapies to market faster, pharmaceutical and biotechnology companies are increasingly adopting predictive technologies to improve decision-making.
Related articles:
- QuantHealth secures $2 million in funding from Accenture and other investors to deliver AI-powered clinical trial simulations
- QuantHealth announces $15 million Series A to use AI to enhance success of clinical trials
- Zenity raises $125 million Series C as AI agent security startup accelerates global expansion
QuantHealth’s technology allows pharmaceutical companies to simulate clinical trials before enrolling patients or committing significant capital. Instead of relying primarily on historical benchmarks and subjective assumptions, companies can use AI-driven simulations to test different trial designs, identify risks and optimize decisions before launching real-world studies.
“Today, clinical development decisions are still largely made through real-world iteration, running trials, waiting for results, and adjusting at significant cost and risk. We’re fundamentally changing that model,” said Orr Inbar, CEO and co-founder of QuantHealth. “With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital.”
To date, QuantHealth has simulated more than 600 clinical trials across 30 medical indications, achieving predictive accuracy levels of up to 90%, according to the company. It plans to expand coverage to more than 40 indications, focusing on areas including oncology, cardiometabolic diseases and inflammatory diseases.
The company says its platform is already used by 12 of the world’s top 20 pharmaceutical companies, helping them optimize trial design, reduce risk and improve development timelines.
